France Moves Towards Gentech Legal Framework
The French Senate has now adopted a series of amendments regulating research, development, production and the use of products based on genetic and cellular engineering techniques in the pharmaceutical industry. The text of the amendments brings these products into the framework of legislation covering pharmaceutical products, and will be examined in detail by the National Assembly and a mixed commission in May, before being regarded as definitive.
The move came on the initiative of a member of parliament, Claude Huriet, at a time when clinical trials of these products are increasing rapidly - an estimated 140 worldwide at the end of 1995, of which 110 were in the USA and 12 in France.
The Franco-American drugmaker Rhone-Poulenc Rorer, along with Transgene and Genset in France, is investing considerable sums in R&D in this sector, with R-PR's Gencell division alone accounting for an annual investment of 600 million francs ($116.9 million).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze